Status:
COMPLETED
Atovaquone for Treatment of COVID-19
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the current study is to accelerate the use of a clinically available therapeutic already FDA-approved for other indications in the setting of pandemic COVID-19 addressing a serious and ...
Detailed Description
Design of the ATaQ COVID-19 Trial: The purpose of the current study is to accelerate the use of a clinically available therapeutic already FDA-approved for other indications in the setting of pandemi...
Eligibility Criteria
Inclusion
- Diagnosis of COVID-19 by positive RT-PCR requiring hospitalization within 72 hours
- Age ≥18 years old
- Able to provide informed consent, or (as allowed by IRB), immediate availability of designated legally authorized representative to provide consent by proxy
- Anticipated hospitalization for \>48 hours
Exclusion
- Participation in any other clinical trial with antiviral activity against COVID-19
- Breastfeeding women
- Known hypersensitivity to atovaquone or formulation excipient
- Active treatment with rifampin
- HIV patients with AIDS requiring treatment for Pneumocystis jirovecii or Toxoplasma gondii
- Not expected to survive for 72 hours. 7) \>14 days from symptom onset
Key Trial Info
Start Date :
July 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04456153
Start Date
July 22 2020
End Date
January 31 2021
Last Update
December 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Medical Center
Dallas, Texas, United States, 75390